Introduction {#Sec1}
============

Colorectal adenocarcinoma is the third most common malignancy worldwide and a leading cause of cancer-related mortality, and its occurrence is increasing \[[@CR1]\]. Multimodal therapies such as surgery, chemotherapy, and radiotherapy have been the typical first-line therapies for colorectal adenocarcinoma. Recently, the tumour microenvironment has been emphasized, and analyses of the interactive relationships between tumour cells and the immune environment have received much attention. Regulation of the immune system through immune checkpoint inhibitors is an emerging therapeutic approach. Immunotherapies that target programmed cell death-ligand 1 (PD-L1) or programmed cell death-1 (PD-1) inhibitors have become cornerstones of treatments for malignant tumours such as gastrointestinal, pulmonary, renal cell carcinoma, and melanoma \[[@CR2]--[@CR5]\].

In colorectal adenocarcinoma, PD-L1 or PD-1 expression, tumour mutational burden (TMB), tumour-infiltrating lymphocytes (TIL), and microsatellite instability (MSI) have been accepted as fundamental biomarkers that guide the clinical application of immune checkpoint inhibitors based on the following lines of evidence \[[@CR6]\]: 1) PD-L1 expression is significantly associated with favourable \[[@CR7]\] or unfavourable \[[@CR8]--[@CR10]\] prognostic values except some studies \[[@CR11], [@CR12]\], and blocking PD-L1/PD-1 interaction can prolong tumour suppression and stabilize the progression of advanced cancers \[[@CR13]\]; 2) the response rate to immune checkpoint inhibitors is significantly associated with increased tumour mutation burden \[[@CR14]\]; 3) PD-L1-positive tumour cells and CD8-positive TIL are key prognostic biomarkers for locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy \[[@CR15]\]; 4) MSI is significantly associated with a prolonged response rates and favourable clinical outcomes in colorectal and non-colorectal cancer patients treated with immune checkpoint inhibitors \[[@CR16]\].

Immunotherapeutic agents are recommended to limited subpopulations of patients based on biomarker expression patterns that have been associated with clinical efficacy and response rates. Representative biomarkers for tumour immune microenvironments are required to distinguish responsive patient subgroups and to predict therapeutic outcomes. However, difficult hurdles remain for deciphering tumour immune microenvironments, pioneering representative novel biomarkers, and stratifying immunotherapy-targetable patients because of the multiplicity of immunotherapy agents, tumour heterogeneity, variable immune suppression mechanisms, and the complexity of interactions between tumours and patients' immune systems \[[@CR17]\]. To date, in colorectal adenocarcinoma, selection criteria that can reliably detect specific subgroups of patients whose tumours will respond to available immunotherapies are lacking. Therefore, further elucidation of clinical response in patients whose tumours have specific combinations of representative biomarkers is imperative.

In the present study, we categorized 489 colorectal adenocarcinomas into four tumour immune microenvironment types (TMIT) based on representative biomarkers such as PD-L1 expression and the presence of TIL. We also conducted clinicopathologic and prognostic analyses with each TMIT, and from the results, we propose an immunotherapy-targetable subgroup.

Materials and methods {#Sec2}
=====================

Patients and clinicopathologic data {#Sec3}
-----------------------------------

This study was approved by the Institutional Review Board of Gangneung Asan Hospital. We collected 489 cases of primary colorectal adenocarcinomas originating in the mucosa of the colon and rectum that were surgically resected between 2004 and 2012 in Gangneung Asan Hospital (Gangneung, Republic of Korea). Exclusion criteria were as follows: 1) histological diagnosis of a tumour type other than adenocarcinoma, 2) inappropriate numbers of tumour cells, and 3) insufficient preservation of paraffin blocks for tissue microarray (TMA) construction.

Demographic and clinicopathologic data were collected from patient medical records, including the patient's gender and age, surgical resection date, most recent follow-up date, and the patient's local recurrence or survival status. Pathology was assessed using haematoxylin and eosin (H&E)-stained slides. Pathological data included tumour size, location, pTNM stage, the histological subtype, tumour differentiation, lymph node metastasis, and lymph vascular or perineural invasion.

Tissue microarray {#Sec4}
-----------------

Formalin-fixed, paraffin-embedded (FFPE) tissue samples were selected and arrayed using a TMA instrument (Quick-Ray, Unitma Co., Ltd., Seoul, Korea). Briefly, representative areas of each case were reviewed and marked on the H&E-stained slide, and its corresponding FFPE block was sampled with a 2-mm-diameter tissue cylinder. The sampled tissue was transferred to a recipient block. Four μm-thick sections were prepared from TMA blocks for immunohistochemical staining.

Immunohistochemistry {#Sec5}
--------------------

Immunohistochemical (IHC) staining for PD-L1 (SP263; Roche Diagnostics, Tucson, USA; Predilution), PD-1 (EPR4877; Abcam, Cambridge, UK; 1:100), CD8 (SP16; Thermo Fisher Scientific, Runcorn, UK; 1:100), MLH1 (ES05; Leica Biosystems, Newcastle, UK; 1:200), MSH2 (25D12; Leica Biosystems, Newcastle, UK; 1:100), PMS2 (EPR3947; Cell Marque, Hotsprings, USA; predilution), and MSH6 (44; Roche Diagnostics, Tucson, USA; predilution) was conducted using a Bond-Max automated immunostaining device (Leica Biosystems, Newcastle, UK) or a Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, USA) based on the manufacturer's recommendations. As positive controls, we used placenta for PD-L1, tonsil for PD-1 and CD8, and colon carcinoma for MLH1, MSH2, PMS2, and MSH6. Negative controls were performed by omitting the primary antibody. Representative stains for PD-L1, CD8, and PD-1 are shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Immunohistochemical staining of PD-L1, CD8, and PD-1. Intensities for positive PD-L1 immunohistochemical stains with a membranous pattern are graded as weak (**a**), moderate (**b**), and strong (**c**), and a negative pattern is shown in (**d**). High expression of CD8 (**e**) and PD-1 (**f**) are also revealed on the tumour bed (magnification: A-F, 400X)

Immunohistochemical analyses {#Sec6}
----------------------------

Immunostaining was assessed blindly by two independent pathologists (BJ NOH and DW EOM). Discrepancies were resolved by simultaneous re-evaluation, and a consensus decision was made.

A semiquantitative assessment for PD-L1 immunoreactivity was obtained by light microscopy. Membranous immunostaining was interpreted based on the proportion and intensity of positive tumour cells. Intensity was graded as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The proportion of positive tumour cells was graded as 0 (negative), 1 (\< 1%), 2 (1--10%), 3 (11--50%), or 4 (\> 50%). Immunoreactive scores (IRS) were calculated by summing these values, culminating in final values ranging from 0 to 7. Positive PD-L1 expression was defined as an IRS value of ≥3.

Immunostaining of PD-1 and CD8 in immune cells was estimated for TIL on the tumour bed area including the tumour epithelium and intratumour stroma by light microscopy (400X; BX51; Olympus, Tokyo, Japan). Five non-contiguous areas including the densest immune cells were selected to ensure that the samples were representative and to increase homogeneity. The numbers of immune cells in the five fields were combined and then averaged to calculate the mean value for one 200X microscopic field (0.1590 mm^2^/field). Mean values (PD-1, 19.0; CD8, 35.0) were utilized as cut-off values to categorize the PD-1 and CD8 expression levels for TIL as "high" or "low".

A four-tiered classification of TMIT was applied as follows: Type I, positive PD-L1 expression in tumour cells and high CD8 expression in TIL; Type II, negative PD-L1 expression in tumour cells and low CD8 expression in TIL; Type III, positive PD-L1 expression in tumour cells and low CD8 expression in TIL; and Type IV, negative PD-L1 expression in tumour cells and high CD8 expression in TIL. These subgroups have been proposed to determine immunotherapy-targetable patients that are predictive for the best response rates \[[@CR18]\].

Statistical analysis {#Sec7}
--------------------

Statistical analysis was conducted using SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA). Categorical data were analysed with chi-squared or Fisher's exact tests. Survival curves were illustrated using the Kaplan-Meier method, and log-rank tests were used to calculate relationships between survival rates and various clinicopathologic factors in univariate analyses. We also estimated the prognostic significance using Cox proportional hazards modelling in multivariate analyses. Statistical significance was defined as *p* \<  0.05.

Results {#Sec8}
=======

Clinicopathologic characteristics {#Sec9}
---------------------------------

Demographics with baseline clinicopathologic characteristics are listed in Table [1](#Tab1){ref-type="table"}. Patients' ages ranged from 31 to 93 years (mean, 66.6 years; standard deviation (SD), 11.5 years). The male-to-female ratio was 1.51, with a male preponderance. The follow-up period after surgical resection ranged from one day to 164.8 months (mean, 58.3 months; median, 57.0 months). Table 1DemographicsParametersNo. of Cases (%)Age Less than 67 yrs212 (43.4) More than 67 yrs277 (56.6)Sex Male294 (60.1) Female195 (39.9)Size Less than 4.9 cm256 (524) More than 4.9 cm233 (47.6)Location Ascending110 (22.5) Transverse to sigmoid242 (49.5) Rectum122 (24.9) NA^a^15 (3.1)Histologic type Intestinal type480 (98.2) Mucinous type9 (1.8)Differentiation Well52 (10.6) Moderately410 (83.8) Poorly18 (3.7) NA^a^9 (1.8)Lymphovascular invasion Absence327 (66.9) Presence145 (29.7) NA^a^17 (3.5)Perineural invasion Absence299 (61.1) Presence52 (10.6) NA^a^138 (28.2)pT category pT1--281 (16.6) pT3354 (72.4) pT454 (11.0)Lymph node metastasis Absence276 (56.4) Presence213 (43.6)Stage I65 (13.3) II206 (42.1) III196 (40.1) IV22 (4.5)Deficient mismatch repairColon Absence335 (91.0) Presence33 (9.0)Rectum Absence113 (93.4) Presence8 (6.6)Chemo-or Radiotherapy Only surgical resection179 (36.6) Adjuvant chemotherapy267 (54.6) Neoadjuvant chemoradiotherapy14 (2.9) Adjuvant chemoradiotherapy29 (5.9)Local recurrence Negative304 (61.8) Positive185 (37.8)Disease-specific death Alive291 (59.7) Dead197 (40.3)PD-1 expression Low304 (62.2) High177 (36.4) NA^a^8 (1.6)CD8 expression Low305 (62.4) High173 (35.4) NA^a^11 (2.2)PD-L1 expression Negative302 (61.8) Positive179 (36.6) NA^a^8 (1.6)Tumour microenvironment immune type Type I (PD-L1+/CD8H)90 (18.4) Type IV (PD-L1−/CD8H)83 (17.0) Type III (PD-L1+/CD8L)87 (17.8) Type II (PD-L1−/CD8L)218 (44.6) NA^a^11 (2.2)^a^Not assessable due to no clinical information, cautery artifact, fragmentation, or incorrect orientation of tumour tissues

From a total of 489 patients, samples without assessable staining due to cautery artifact, fragmentation, or incorrect orientation of tumour tissues were excluded for PD-L1, PD-1, CD8, and deficient mismatch repair (dMMR). Positive PD-L1, high PD-1, and high CD8 expression were detected in 179 (36.6%), 177 (36.4%), and 173 (35.4%) samples, respectively. We classified each tumour sample into a TMIT according to immunohistochemical results and arranged the TMIT in order of prognostic value (type I, IV, III, and II) as follows: Type I, 90 samples (18.4%); Type IV, 83 (17.0%); Type III, 87 (17.8%); and Type II, 218 (44.6%). dMMR was seen in 41 samples (8.4%) (33 samples (9.0%) in colon; 8 samples (6.6%) in rectum).

Clinicopathological correlation of TMIT and CD8 expression {#Sec10}
----------------------------------------------------------

Clinicopathological relationships between TMIT and CD8 or PD-L1 expression are delineated in Table [2](#Tab2){ref-type="table"}. TMIT I demonstrates a more significant association with low T category (*p* \<  0.001) and decreased lymph node metastasis (*p* = 0.001), culminating in favourable survival (*p* = 0.002) benefit and decreased local recurrence (*p* = 0.031), than the other TMIT. In addition, Type I tended to dMMR (*p* = 0.006). Table 2Clinicopathologic correlation of tumour microenvironment immune types, CD8 expression, and PD-L1 expressionParametersTumour microenvironment immune type (%)CD8 expression (%)PD-L1 expression (%)Type I(PDL1+/CD8H)Type IV(PD-L1−/CD8H)Type III(PD-L1+/\
CD8L)Type II\
(PD-L1−/CD8L)*P*LowHigh*P*Neg.Pos.*P*AgeLess than 67 yrs36 (17.4)36 (17.4)35 (16.9)100 (48.3)0.366135 (65.2)72 (34.8)0.575136 (65.4)72 (35.6)0.303More than 67 yrs54 (19.9)47 (17.3)52 (19.2)118 (43.5)170 (62.7)101 (37.3)166 (60.8)107 (39.2)SexMale58 (20.3)57 (19.9)46 (16.1)125 (43.7)0.094171 (59.8)115 (40.2)**0.026\***182 (63.2)106 (36.8)0.821Female32 (16.7)26 (13.5)41 (21.4)93 (48.4)134 (69.8)58 (30.2)120 (62.2)73 (37.8)SizeLess than 4.9 cm50 (20.0)48 (19.2)43 (17.2)109(43.6)0.227152 (60.8)98 (39.2)0.15 l2157 (62.5)94 (37.5)0.911More than 4.9 cm40 (17.5)35 (15.4)44 (19.3)109 (47.8)153 (67.1)75 (32.9)145 (63.0)85 (37.0)LocationAscending26 (24.3)18 (16.8)22 (20.6)41 (38.3)0.91263 (58.9)44 (41.1)0.84959 (54.6)49 (45.4)0.517Transverse tosigmoid34 (14.2)41 (17.2)42 (17.6)122 (51.0)164 (68.6)75 (31.4)164 (68.3)76 (31.7)Rectum27 (23.1)22 (18.8)20 (17.1)48 (41.0)68 (58.1)49 (41.9)70 (59.3)48 (40.7)Histologic typeIntestinal type89 (18.9)83 (17.7)87 (18.5)211 (44.9)0.080298 (63.4)172 (36.6)0.160295 (62.4)178 (37.6)0.145Mucinous type1 (12.5)0 (0.0)0 (0.0)7 (87.5)7 (87.5)1 (12.5)7 (87.5)1 (12.5)DifferentiationWell9 (17.6)14 (27.5)8 (15.7)20 (39.2)0.79528 (54.9)23 (45.1)0.45834 (65.4)18 (34.600.483Moderately75 (18.7)66 (16.5)76 (19.0)184 (45.7)260 (64.8)141 (35.2)251 (62.3)152 (37.7)Poorly5 (27.8)3 (16.7)3 (16.7)7 (38.9)10 (55.6)8 (44.4)10 (55.6)8 (44.4)Lymphovascular invasionAbsence65 (20.4)47 (14.8)58 (18.2)148 (46.5)0.955206 (64.8)112 (35.2)0.503196 (61.1)125 (38.9)0.211Presence21 (14.7)34 (23.8)26 (18.2)62 (43.4)88 (61.5)55 (38.5)96 (67.1)47 (32.9)Perineural invasionAbsence58 (19.7)43 (14.6)59 (20.0)135 (45.8)0.650194 (65.8)101 (34.2)0.808178 (60.3)117 (39.7)0.116Presence7 (14.0)11 (22.0)7 (14.0)25 (50.0)32 (64.0)18 (36.0)36 (72.0)14 (28.0)pT categorypT1--226 (32.9)17 (21.5)15 (19.0)21(26.6)**\<  0.001\***36 (45.6)43 (54.4)**0.001\***178 (60.3)117 (39.7)**0.001\***pT358 (16.8)56 (16.2)65 (18.8)166(48.0)231 (67.0)114 (33.0)36 (72.0)14 (28.0)pT46 (11.1)10 (18.5)7 (13.0)31 (57.4)38 (70.4)16 (29.6)178 (60.3)117 (39.7)Lymph node metastasisAbsence68 (25.3)43 (16.0)47 (17.5)111 (41.3)**0.001\***158 (58.7)111(41.3)**0.009\***154 (56.8)117 (43.2)**0.002\***Presence22 (10.5)40 (19.1)40 (19.1)107 (51.2)147 (70.3)62 (29.3)148 (70.5)62 (29.5)StageI24 (37.5)11 (17.2)11 (17.2)18 (28.1)**0.001\***29 (45.3)35 (54.7)**0.006\***29 (45.3)35 (54.7)**0.003\***II41 (20.5)30 (15.0)34 (17.0)95 (47.5)129 (64.5)71 (35.5)125 (61.9)77 (38.1)III21 (10.9)38 (19.6)38 (19.8)95(19.5)133 (69.3)59(30.7)134 (69.4)59 (30.6)IV4 (18.2)4 (18.2)4 (18.2)10 (45.5)14 (63.6)8 (36.4)14 (63.6)8 (36.4)Deficient mismatch repairAbsence76 (17.3)76 (17.3)81 (18.5)206 (46.9)**0.006\***287 (65.4)152 (34.6)**0.017\***283 (64.2)158 (35.8)**0.037\***Presence14 (35.9)7 (17.9)6 (15.4)12 (30.8)18 (46.2)21 (53.8)19 (47.5)21 (52.5)Neoadjuvant chemoradiotherapyAbsent88 (18.2)77 (16.5)86 (18.5)215 (46.1)**0.025\***301 (64.6)165 (35.4)**0.026\***293 (62.5)176 (37.5)0.375Present2 (16.7)6 (50.0)1 (8.3)3 (25.0)4 (33.3)8 (66.7)9 (75.0)3 (25.0)Local recurrenceAbsence67 (22.3)51 (17.0)52 17.3)130 (43.3)**0.031\***182 (60.7)118 (39.3)0.064181 (59.9)121 (40.1)0.093Presence23 (12.9)32 (18.0)35 (19.7)88 (49.4)123 (69.1)55 (30.9)121 (67.6)58 (32.4)Disease-specific deathAlive69 (24.0)49 (17.1)48 (16.7)121 (42.2)**0.002\***169 (58.9)118 (41.1)**0.006\***170 (58.8)119 (41.2)**0.027\***Dead21 (11.0)34 (17.8)39 (20.4)97 (50.8)136 (71.2)55 (28.8)132 (68.8)60 (31.3)Cases without clinical information or for which data are not assessable due to cautery artifact, fragmentation, or incorrect orientation of tumour tissues are excluded from statistical analyses

High CD8 expression is significantly associated with male gender (*p* = 0.026), low T category (*p* = 0.001), and no lymph node metastasis (*p* = 0.009). Notably, Patients with neoadjuvant chemoradiotherapy significantly increase CD8 expression (*p* = 0.026).

Positive PD-L1 expression is also significantly associated with low T category (*p* = 0.001) and no lymph mode metastasis (*p* = 0.002). However, there is no relation to neoadjuvant chemoradiotherapy (*p* = 0.375).

Relationships among biomarkers of the tumour microenvironment are shown in Table [3](#Tab3){ref-type="table"}. Positive PD-L1 expression is significantly associated with dMMR, high CD8 expression, and high PD-1 expression (*p* = 0.037, *p* \<  0.001, *p* \<  0.001, respectively). High CD8 expression is also detected in tumour samples with high PD-1 expression (*p* \<  0.001) and dMMR (*p* = 0.017). Table 3Relationships among expression of PD-L1, CD8, and PD-1 with deficient mismatch repairParametersPD-L1 expression (%)CD8 expression (%)NegativePositive*P*LowHigh*P*CD8 expressionLow218 (71.5)87 (28.5)**\<  0.001\***------High83 (48.0)90 (52.0)------PD-1 expressionLow214 (70.4)90 (29.6)**\<  0.001\***238 (78.8)64 (21.2)**\<  0.001\***High88 (49.7)89 (50.3)67 (38.1)109 (61.9)Deficient mismatch repairAbsence283 (64.2)158 (35.8)**0.037\***287 (65.4)152 (34.6)**0.017\***Presence19 (47.5)21 (52.5)18 (46.2)21 (53.8)Cases without clinical information or with unassessable data due to cautery artifact, fragmentation, or incorrect orientation of tumour tissues are excluded from statistical analyses

Univariate and multivariate analyses for overall survival {#Sec11}
---------------------------------------------------------

In univariate analyses for overall survival (OS) with the log-rank method (Table [4](#Tab4){ref-type="table"}), the dependence of clinical prognosis is significant for TMIT (*p* \<  0.001); PD-L1 (*p* = 0.007), CD8 (*p* = 0.002), and PD-1 (*p* = 0.001) expression levels; and several clinicopathological parameters, such as patient age (*p* \<  0.001), lymph vascular invasion (*p* \<  0.001), perineural invasion (*p* = 0.003), and pTNM stage (*p* \<  0.001). The TMIT I subgroup is associated with better OS than other TMIT. The TMIT II subgroup is associated with the worst OS. PD-L1 positivity, high CD8, or high PD-1 expression is significantly associated with favourable OS (Kaplan-Meier curve, Fig. [2](#Fig2){ref-type="fig"}). Notably, dMMR (*p* = 0.014) and chemo- or radiotherapy (*p* \<  0.001) are generally also associated with favourable clinical outcomes. Table 4Univariate analysis (Log-rank test) for overall survivalParametersMean Survival (Months)Confidence Interval (95%)*P*LowerUpperAgeLess than 67 yrs116.5107.2125.8**\<  0.001\***More than 67 yrs87.660.385.9SexMale103.995.7112.20.330Female94.183.3105.0SizeLess than 4.9 cm92.684.1101.00.109More than 4.9 cm107.297.6116.8LocationAscending100.284.6115.70.716Transverse to sigmoid98.990.3107.6Rectum95.883.4108.1Histologic typeIntestinal type101.194.4107.80.856Mucinous type82.055.6108.3DifferentiationWell106.490.5122.20.117Moderately99.892.5107.0Poorly88.461.1115.7Lymphovascular invasionAbsence109.8101.7117.8**\<  0.001\***Presence77.366.688.0Perineural invasionAbsence94.987.2102.6**0.003\***Presence68.052.184.0pT categorypT1--2112.299.9124.4**\<  0.001\***pT3100.392.6108.1pT473.854.792.8Lymph node metastasisAbsence113.3104.6122.0**\<  0.001\***Presence84.975.294.6StageI100.988.4113.4**\<  0.001\***II113.8103.8123.7III88.978.799.1IV37.219.754.6Deficient mismatch repairAbsence98.992.0105.8**0.014\***Presence126.8105.8147.8Chemo- or radiotherapyAbsence83.372.194.4**\<  0.001\***Presence109.5101.7117.4Local recurrenceAbsence147.6142.1153.2**\<  0.001\***Presence42.237.446.9PD-1 expressionLow93.284.5101.9**0.001\***High109.299.9118.5CD8 expressionLow92.483.9101.0**0.002\***High114.8104.4125.2PD-L1 expressionNegative94.986.3103.4**0.007\***Positive107.197.7116.6Tumour microenvironmentimmune typeType I (PD-L1+/CD8H)122.1110.2133.9**\<  0.001\***Type III (PD-L1+/CD8L)& Type IV (PD-L1−/CD8H)96.985.8108.0Type II (PD-L1−/CD8L)92.482.2102.6Cases with no clinical information or for which the data are not assessable due to cautery artifact, fragmentation, or incorrect orientation of tumour tissues are excluded in statistical analyses Fig. 2Kaplan-Meier curves of overall survival

In multivariate survival analyses with the Cox proportional hazard model (Table [5](#Tab5){ref-type="table"}), the TMIT I subgroup has the best survival benefit, and the TMIT II subgroup has the worst survival benefit, while the TMIT III and IV subgroups have intermediate survival benefits. Low CD8 expression is also an independent and unfavourable prognosticator for OS, in addition to higher pTNM stage, more than 67 years in age, lymph vascular invasion, and only surgical resection without chemo- or radiotherapy. Table 5Multivariate analysis (Cox proportional hazards model)ParametersMultivariate (TMIT)Multivariate (PD-L1/CD8 TIL)HR95% CI*P*HR95% CI*P*TMIT**0.022\*--**Type III & IV vs. Type I1.8311.122--2.989**0.015\***------Type II vs. Type I1.9551.208--3.164**0.006\***------CD8Low vs. high expression----**--**1.4061.021--1.936**0.037\***PD-L1Positive vs. Negative expression----**--**1.2390.903--1.7000.184pT category**\<  0.001\*\<  0.001\***pT3 vs. pT1--22.0291.209--3.406**0.007\***2.0721.230--3.488**0.006\***pT4 vs. pT1--23.7162.027--6.813**\<  0.001\***3.8382.092--7.039**\<  0.001\***Lymph nodemetastasisPresence vs. Absence1.8991.408--2.561**\<  0.001\***1.9551.450--2.636**\<  0.001\***Deficient mismatch repairAbsence vs. Presence1.7800.871--3.6400.1141.8270.894--3.7320.098AgeMore than 67 vs. less than 67 years1.6871.224--2.326**0.001\***1.6621.207--2.290**0.002\***Chemotherapy or RadiotherapyOnly resection vs. Resection with chemo- or radiotherapy2.0391.491--2.789**\<  0.001\***2.0861.526--2.852**\<  0.001\****CI* confidence interval, *HR* hazard ratio, *TIL* tumour-infiltrating lymphocytes, *TMIT* tumour microenvironment immune type

Discussion {#Sec12}
==========

A four-tiered classification for tumour microenvironment immune type (TMIT) has been proposed to describe the patient's immune status and to determine immunotherapy-responsive subgroups \[[@CR18]\]. Each TMIT is defined as follows: Type I, PD-L1 positivity with TIL (adaptive immune resistance); Type II, PD-L1 negativity with no TIL (immune ignorance); Type III, PD-L1 positivity with no TIL (intrinsic induction); and Type IV, PD-L1 negativity with TIL (possible role of other suppressors in producing immune tolerance). In this study, we corroborated the prognostic implications for each TMIT assigned to the colorectal adenocarcinomas according to PD-L1 expression and TIL. Types I and II were associated with the best and worst prognoses, respectively, while Types III and IV had intermediate outcomes in the overall survival analyses.

In colorectal adenocarcinoma, the prognostic value of PD-L1 expression has been contradictory*.* Our results are consistent with those of *Huang* et al. \[[@CR7]\], who demonstrated that high PD-L1 expression on tumour cells was associated with improved disease-free survival and overall survival. Some studies \[[@CR8]--[@CR10]\] indicated that PD-L1-positive immunoreactivity on tumour cells was a significant predictor of unfavourable overall, disease-free, or recurrence-free survival in colorectal adenocarcinoma. However, other studies \[[@CR11], [@CR12]\] reported that PD-L1 expression in tumour cells was not associated with clinical prognosis, regardless of MSI. Plausible explanations for these contradictory prognostic values for PD-L1 expression are as follows: 1) various methodologies such as different primary antibodies and arbitrary cut-off values for PD-L1 immune expression, 2) tumour heterogeneity, 3) diverse patient populations, and 4) complex interactions of tumour immune microenvironments. To enhance the representativeness and overcome tumour heterogeneity, five non-contiguous microscopic hotspots representing the densest immune or tumour cells were selected. Additionally, we attempted to simplify the complexity of assessing the tumour immune microenvironment using a more concise and representative set of immune biomarkers, such as PD-L1, PD-1, and CD8.

In contrast with contradictory results for PD-L1 expression, CD8 overexpression has been a constantly favourable prognostic factor in many studies \[[@CR15], [@CR19], [@CR20]\]. Especially, neoadjuvant chemoradiotherapy enhances CD8 expression as shown in our study.

Pathogenetic analysis for TIL, which are intermingled with tumour cells, plays a crucial role in interpreting tumorigenesis and predicting a clinical biologic outcome. TIL can boost PD-L1 expression in tumour cells in an interferon-gamma (IFN-γ)-dependent manner. PD-L1 overexpression can, in turn, trigger apoptosis and immune tolerance of T-cells \[[@CR21]\]. IFN-γ facilitates PD-L1 expression in tumour cells through the JAK-STAT (signal transducer and activator of transcription) pathway \[[@CR22]\]. Therefore, CD8-positive TIL in the stroma of colorectal adenocarcinoma is significantly associated with positive PD-L1 expression. Capitalizing on this background and consistent with the positive correlation of PD-1 expression with CD8 and PD-L1 expression as shown in our study, patients with TMIT I tumours can represent a stronger CD8/PD-L1/PD-1 interaction compared to other TMIT subgroups. A more patent CD8/PD-L1/PD-1 concurrence is a strong indicator that immune checkpoint inhibitors such as PD-L1 or PD-1 blockers are more effective for colorectal adenocarcinoma patients in the TMIT I subgroup.

PD-L1 overexpression in colorectal adenocarcinoma is implicated in increased tumour mutation burden, MSI, and upregulated immune-related genes \[[@CR23]--[@CR25]\]. *Ock* et al. \[[@CR26]\] reported that the TMIT I subgroup is related to a high mutation burden and PD-L1 amplification. *Madore* et al. \[[@CR27]\] reported that PD-L1-positive tumours in stage III melanoma had increased levels of immune-associated genes, suggesting that PD-L1 expression indicates an upregulation of cytotoxic (CD8) T-cell- or macrophage-related genes. Clues gleaned from these recent studies combined with our results suggest that PD-L1 overexpression in colorectal adenocarcinoma is canonically or non-canonically associated with increased antigenic recognition of tumours (anti-tumorigenicity by TIL) through MSI, increased tumour mutation burden or IFN-γ secretion by TIL, although elucidating these pathogenetic mechanisms needs further study.

To date, few studies of colorectal adenocarcinoma have attempted to classify tumour microenvironment complexity with multiple immune markers to identify specific subpopulations of colorectal adenocarcinoma patients for evidence-based, targeted immune therapies. *Chen* et al. \[[@CR15]\] reported that both PD-L1 positivity and CD8-high TIL predict favourable clinical outcomes for locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy. Notably, *Huang* et al. \[[@CR7]\] reported results consistent with our study: the subgroup of patients with high CD8-high TIL and high PD-L1 expression in tumour cells have better survival outcomes than other subgroups. These integrative analyses with multiple biomarkers underscore the importance of evaluating both PD-L1 expression and TIL infiltration to determine the subgroup responsive to immune checkpoint inhibitors.

Collective lines of evidence support that the TMIT I subgroup (PD-L1-positive tumour cells and high CD8-positive TIL) is associated with the following favourable biologic behaviours: 1) high CD8-positive TIL is a favourable prognosticator; 2) PD-L1 expression is closely linked to immune reactivation through an increased tumour mutation burden and upregulated immune-related genes; 3) In colorectal adenocarcinomas, MSI significantly associated with PD-L1 expression in tumour cells have a favourable clinical prognosis; 4) the blocking capacity of immune checkpoint inhibitors is significantly correlated with an increased tumour mutation burden that is indicated by PD-L1 overexpression \[[@CR14]\].

In summary, we ascertained the prognostic value of a four-tiered classification of tumour microenvironment immune types (TMIT) in colorectal adenocarcinomas according to PD-L1 expression and TIL status. Type I (both PD-L1-positive tumour cells and high-CD8 TIL) and Type II (PD-L1-negative tumour cells and low-CD8 TIL) are associated with the best and worst prognoses, respectively. Positive PD-L1 expression is significantly associated with dMMR and correlated with high-CD8 or PD-1 overexpression of TIL, which indicates that the TMIT I subgroup represents a stronger CD8/PD-L1/PD-1 interaction than the other TMIT. Therefore, the TMIT I subgroup may be a beneficial candidate to predict a better response rate to immune checkpoint inhibitors by hindering CD8/PD-L1/PD-1 interaction and giving rise to immune reactivation. Based on their tumour microenvironment immune reactions, such categorized immune subgroups of colorectal cancers can be predictive for clinical prognosis. TMIT classification also provides helpful options for determining which subgroups are immunotherapy-targetable to elicit an effective response.

Conclusion {#Sec13}
==========

TMIT I (both PD-L1-positive tumour cells and high-CD8 TIL) is associated with the best prognosis, and shows stronger CD8/PD-L1/PD-1 signalling interaction compared to the other TMIT. Therefore, we propose that the TMIT I subgroup is a candidate TMIT to predict effective response rate for existing immune checkpoint inhibitors and determine targetable subgroups for emerging therapies.
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